GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:PLED BTA) » Definitions » Cyclically Adjusted PS Ratio

Egetis Therapeutics AB (OSTO:PLED BTA) Cyclically Adjusted PS Ratio : (As of Jul. 03, 2025)


View and export this data going back to . Start your Free Trial

What is Egetis Therapeutics AB Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Egetis Therapeutics AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Cyclically Adjusted PS Ratio Chart

Egetis Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.25 8.21 9.96 8.42 11.69

Egetis Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.35 7.40 8.46 11.69 6.83

Competitive Comparison of Egetis Therapeutics AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted PS Ratio falls into.


;
;

Egetis Therapeutics AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Egetis Therapeutics AB's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.466/132.8245*132.8245
=0.466

Current CPI (Mar. 2025) = 132.8245.

Egetis Therapeutics AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.000 99.995 0.000
201509 0.000 100.228 0.000
201512 0.000 100.276 0.000
201603 0.000 100.751 0.000
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.005 102.752 0.006
201709 0.000 103.279 0.000
201712 0.498 103.793 0.637
201803 0.027 103.962 0.034
201806 0.354 104.875 0.448
201809 0.246 105.679 0.309
201812 0.407 105.912 0.510
201903 2.013 105.886 2.525
201906 0.163 106.742 0.203
201909 0.226 107.214 0.280
201912 0.625 107.766 0.770
202003 0.429 106.563 0.535
202006 0.788 107.498 0.974
202009 0.094 107.635 0.116
202012 0.179 108.296 0.220
202103 0.139 108.360 0.170
202106 0.918 108.928 1.119
202109 0.227 110.338 0.273
202112 0.121 112.486 0.143
202203 0.260 114.825 0.301
202206 0.172 118.384 0.193
202209 0.187 122.296 0.203
202212 0.205 126.365 0.215
202303 0.249 127.042 0.260
202306 0.216 129.407 0.222
202309 0.447 130.224 0.456
202312 1.195 131.912 1.203
202403 0.444 132.205 0.446
202406 0.510 132.716 0.510
202409 0.345 132.304 0.346
202412 0.396 132.987 0.396
202503 0.466 132.825 0.466

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Egetis Therapeutics AB  (OSTO:PLED BTA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Egetis Therapeutics AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines